These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 3717150)
21. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Bellur SS; Lepeytre F; Vorobyeva O; Troyanov S; Cook HT; Roberts IS; Kidney Int; 2017 Jan; 91(1):235-243. PubMed ID: 27914703 [TBL] [Abstract][Full Text] [Related]
22. Relationship between urinary fibrinogen degradation products and various types of chronic nephritis. Sakakibara K; Nagase M; Takada Y; Takada A Thromb Res; 1987 Feb; 45(4):403-11. PubMed ID: 3576523 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of urinary fibrin/fibrinogen degradation products (FDP) as measured by latex photometric immunoassay in renal diseases. Kaizu K; Ito Y; Uriu K; Eto S Nihon Jinzo Gakkai Shi; 1993 Jan; 35(1):29-34. PubMed ID: 8336397 [TBL] [Abstract][Full Text] [Related]
24. Does measurement of urinary rare proteins provide diagnostic significance in glomerular diseases? Nagase M; Sakakibara K; Honda N; Takada Y; Takada A Contrib Nephrol; 1988; 68():141-8. PubMed ID: 3069315 [No Abstract] [Full Text] [Related]
25. [Significance of urinary fibrin/fibrinogen degradation product (FDP) D-dimer measured by highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases]. Shibata T; Magari Y; Mizunaga S; Okabe E; Sumie A; Ishii T; Tomo T; Yasumori R; Nasu M Nihon Jinzo Gakkai Shi; 1994 Jul; 36(7):805-12. PubMed ID: 8072218 [TBL] [Abstract][Full Text] [Related]
26. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects. Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212 [TBL] [Abstract][Full Text] [Related]
27. Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Wasilewska A; Zoch-Zwierz W; Taranta-Janusz K; Kołodziejczyk Z Scand J Urol Nephrol; 2011 Feb; 45(1):52-9. PubMed ID: 21034351 [TBL] [Abstract][Full Text] [Related]
29. Renal disease in pregnancy. Three controversial areas: mesangial IgA nephropathy, focal glomerular sclerosis (focal and segmental hyalinosis and sclerosis), and reflux nephropathy. Kincaid-Smith P; Fairley KF Am J Kidney Dis; 1987 Apr; 9(4):328-33. PubMed ID: 3578269 [TBL] [Abstract][Full Text] [Related]
30. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases. Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315 [TBL] [Abstract][Full Text] [Related]
31. Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function. Colucci M; Semeraro N; Montemurro P; Chiumarulo P; Triggiani R; Morrone LF; Schena FP Kidney Int; 1991 Jun; 39(6):1213-7. PubMed ID: 1910125 [TBL] [Abstract][Full Text] [Related]
32. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis. Michielsen P; Roels L; Vanrenterghem Y; Boel A; van Damme B; Vermylen J Clin Nephrol; 1976 Mar; 5(3):105-13. PubMed ID: 1261101 [TBL] [Abstract][Full Text] [Related]
33. Study of the correlation between glomerular and urinary sediment deposits using immunofluorescent technique. Orfila C; Mignon-Conte M; De Boissezon JF; Suc JM Biomedicine; 1977 Mar; 27(2):89-92. PubMed ID: 324533 [TBL] [Abstract][Full Text] [Related]
34. [Urinary excretion of plasmin and fibrin-fibrinogen degradation products in various types of glomerulonephritis (author's transl)]. Koyama A; Narita M; Ishida H; Fukao K; Tojo S Nihon Jinzo Gakkai Shi; 1979 Sep; 21(9):1037-46. PubMed ID: 160473 [No Abstract] [Full Text] [Related]
35. Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis. Clarkson AR; MacDonald MK; Cash JD; Robson JS Br Med J; 1972 Jul; 3(5821):255-60. PubMed ID: 5046478 [TBL] [Abstract][Full Text] [Related]
36. Urinary thrombin: a novel marker of glomerular inflammation for the diagnosis of crescentic glomerulonephritis (prospective observational study). Kitamoto Y; Arizono K; Fukui H; Tomita K; Kitamura H; Taguma Y; Imamura T PLoS One; 2015; 10(3):e0118704. PubMed ID: 25742509 [TBL] [Abstract][Full Text] [Related]
37. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Haramaki R; Tamaki K; Fujisawa M; Ikedo H; Haramaki N; Okuda S Am J Kidney Dis; 2001 Dec; 38(6):1191-8. PubMed ID: 11728950 [TBL] [Abstract][Full Text] [Related]
38. [ Products of fibrin degradation in the urine during experimental and human glomerulonephritis]. Lagrue G; Hirbec G; Gouault-Heilmann M; Levent M; Branellec A; Moisy M Pathol Biol (Paris); 1975 Jun; 23(6):486-91. PubMed ID: 1105353 [TBL] [Abstract][Full Text] [Related]
39. Urinary platelet factor four (Pf4) levels in mesangial IgA glomerulonephritis and thin basement membrane disease. Taira K; Hewitson TD; Kincaid-Smith P Clin Nephrol; 1992 Jan; 37(1):8-13. PubMed ID: 1541068 [TBL] [Abstract][Full Text] [Related]
40. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB; Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]